• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: an investigational chimeric antigen receptor (CAR) T-cell product that consists of autologous T cells that have been transduced with a genetically engineered replication-incompetent, third-generation, self-inactivating lentiviral vector encoding a G protein-coupled receptor class C, group 5, member D (GPRC5D)-specific CAR
Date Designated: 06/21/2023
Orphan Designation: Treatment of multiple myeloma
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
400 Dexter Avenue N, Suite 1200
Seattle, Washington 98109
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-